GB2405336A - Cholinesterase inhibitors to prevent injuries caused by chemicals - Google Patents
Cholinesterase inhibitors to prevent injuries caused by chemicals Download PDFInfo
- Publication number
- GB2405336A GB2405336A GB0424188A GB0424188A GB2405336A GB 2405336 A GB2405336 A GB 2405336A GB 0424188 A GB0424188 A GB 0424188A GB 0424188 A GB0424188 A GB 0424188A GB 2405336 A GB2405336 A GB 2405336A
- Authority
- GB
- United Kingdom
- Prior art keywords
- chemicals
- injuries caused
- cholinesterase inhibitors
- prevent injuries
- cholinesterase inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Catching Or Destruction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
The invention provides methods for treating and preventing injuries caused by chemicals by administering to a patient a therapeutically effective amount of at least one cholinesterase inhibitor The chemicals can be, for example, agricultural compounds or chemical weapons. In one embodiment, the cholinesterase inhibitor is donepezil, a stereoisomer thereof and/or a pharmaceutically acceptable salt thereof.
Description
GB 2405336 A continuation (74) Agent and/or Address for Service: Elkington
and Fife LLP Prospect House, 8 Pembroke Road, SEVENOAKS, Kent, TN13 1XR, United Kingdom
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US37656002P | 2002-05-01 | 2002-05-01 | |
PCT/US2003/013575 WO2003092606A2 (en) | 2002-05-01 | 2003-05-01 | Cholinesterase inhibitors to prevent injuries caused by chemicals |
Publications (2)
Publication Number | Publication Date |
---|---|
GB0424188D0 GB0424188D0 (en) | 2004-12-01 |
GB2405336A true GB2405336A (en) | 2005-03-02 |
Family
ID=29401361
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB0424188A Withdrawn GB2405336A (en) | 2002-05-01 | 2003-05-01 | Cholinesterase inhibitors to prevent injuries caused by chemicals |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2003228796A1 (en) |
GB (1) | GB2405336A (en) |
WO (1) | WO2003092606A2 (en) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2140868A1 (en) | 2000-03-03 | 2010-01-06 | Eisai R&D Management Co., Ltd. | Use of a cholinesterase inhibitor for the treatment of dementia and cognitive impairments associated with or caused by chemotherapy |
PL1622569T3 (en) | 2003-04-24 | 2016-06-30 | Incyte Holdings Corp | Aza spiro alkane derivatives as inhibitors of metallproteases |
US20050182044A1 (en) * | 2004-02-17 | 2005-08-18 | Bruinsma Gosse B. | Combinatorial therapy with an acetylcholinesterase inhibitor and (3aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3,-b]indol-5-yl phenylcarbamate |
AU2012200612B2 (en) * | 2004-09-24 | 2014-11-20 | The Government Of The United States, As Represented By The Secretary Of The Army | Method of treating organophosphorus poisoning |
US9132135B2 (en) * | 2004-09-24 | 2015-09-15 | University Of Maryland, Baltimore | Method of treating organophosphorous poisoning |
AU2005289808B2 (en) * | 2004-09-24 | 2011-11-03 | The Government Of The United States As Represented By The Secretary Of The Army, U.S. Army Medical Research Institute Of Chemical Defense | Method of treating organophosphorous poisoning |
JP4872044B2 (en) * | 2005-09-30 | 2012-02-08 | 財団法人ヒューマンサイエンス振興財団 | Cardiac remodeling inhibitor and heart failure treatment |
WO2008141081A1 (en) | 2007-05-10 | 2008-11-20 | Amr Technology, Inc. | Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin |
WO2012071369A2 (en) | 2010-11-24 | 2012-05-31 | The Trustees Of Columbia University In The City Of New York | A non-retinoid rbp4 antagonist for treatment of age-related macular degeneration and stargardt disease |
US9333202B2 (en) | 2012-05-01 | 2016-05-10 | The Trustees Of Columbia University In The City Of New York | Non-retinoid antagonists for treatment of age-related macular degeneration and stargardt disease |
US9938291B2 (en) | 2013-03-14 | 2018-04-10 | The Trustess Of Columbia University In The City Of New York | N-alkyl-2-phenoxyethanamines, their preparation and use |
US9944644B2 (en) | 2013-03-14 | 2018-04-17 | The Trustees Of Columbia University In The City Of New York | Octahydropyrrolopyrroles their preparation and use |
US9637450B2 (en) | 2013-03-14 | 2017-05-02 | The Trustees Of Columbia University In The City Of New York | Octahydrocyclopentapyrroles, their preparation and use |
DK2968304T3 (en) | 2013-03-14 | 2019-01-28 | Univ Columbia | 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE. |
DK3137168T3 (en) | 2014-04-30 | 2022-03-21 | Univ Columbia | SUBSTITUTED 4-PHENYLPIPERIDINES, THEIR PREPARATION AND USE |
TWI698436B (en) | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | Pyrrolo and pyrazolopyrimidines as ubiquitin-specific protease 7 inhibitors |
MA41291A (en) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | PYRROLOTRIAZINONE AND IMIDAZOTRIAZINONE DERIVATIVES AS UBIQUE-SPECIFIC PROTEASE INHIBITORS No. 7 (USP7) FOR THE TREATMENT OF CANCER |
US9932351B2 (en) | 2015-02-05 | 2018-04-03 | Forma Therapeutics, Inc. | Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors |
US9938300B2 (en) | 2015-02-05 | 2018-04-10 | Forma Therapeutics, Inc. | Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitors |
JP2018504430A (en) | 2015-02-05 | 2018-02-15 | フォーマ セラピューティクス,インコーポレイテッド | Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5939095A (en) * | 1993-12-10 | 1999-08-17 | Lts Lohmann Therapie-Systeme Gmbh | Transdermal therapeutic system and a process for the combined transdermal application of physostigmine and scopolamine for the prophylaxis and pretreatment of a poisoning caused by highly toxic organophosphorus neurotoxins in particular soman |
US6114347A (en) * | 1993-12-10 | 2000-09-05 | Lts Lohmann Therapie-Systeme Gmbh | Pharmaceutical formulation for the prophylaxis and pretreatment of a poisoning caused by organophosphorus cholinesterase inhibitors |
US6264974B1 (en) * | 1998-07-07 | 2001-07-24 | Salvagnini Italia Spa | Buccal and sublingual administration of physostigmine |
-
2003
- 2003-05-01 WO PCT/US2003/013575 patent/WO2003092606A2/en not_active Application Discontinuation
- 2003-05-01 GB GB0424188A patent/GB2405336A/en not_active Withdrawn
- 2003-05-01 AU AU2003228796A patent/AU2003228796A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5939095A (en) * | 1993-12-10 | 1999-08-17 | Lts Lohmann Therapie-Systeme Gmbh | Transdermal therapeutic system and a process for the combined transdermal application of physostigmine and scopolamine for the prophylaxis and pretreatment of a poisoning caused by highly toxic organophosphorus neurotoxins in particular soman |
US6114347A (en) * | 1993-12-10 | 2000-09-05 | Lts Lohmann Therapie-Systeme Gmbh | Pharmaceutical formulation for the prophylaxis and pretreatment of a poisoning caused by organophosphorus cholinesterase inhibitors |
US6264974B1 (en) * | 1998-07-07 | 2001-07-24 | Salvagnini Italia Spa | Buccal and sublingual administration of physostigmine |
Also Published As
Publication number | Publication date |
---|---|
WO2003092606A2 (en) | 2003-11-13 |
GB0424188D0 (en) | 2004-12-01 |
AU2003228796A8 (en) | 2003-11-17 |
AU2003228796A1 (en) | 2003-11-17 |
WO2003092606A3 (en) | 2004-01-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB2405336A (en) | Cholinesterase inhibitors to prevent injuries caused by chemicals | |
PL373903A1 (en) | A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease | |
BR0212042A (en) | Compound, pharmaceutical composition, method of treating or preventing disease, and use of a compound | |
NO20020978L (en) | Use of inhibitors of the renin-angiotensin system for the prevention of cardiovascular conditions | |
EP1480634A4 (en) | Treating benign prostate hyperplasia with sarms | |
MY141661A (en) | 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
WO2002010137A3 (en) | Indazole derivatives as JNK inhibitors | |
WO2003032914A3 (en) | Methods for treating substance abuse with cholinesterase inhibitors | |
AU7031500A (en) | Therapeutic quinazoline compounds | |
MXPA05006359A (en) | Disease treatment via antimicrobial peptide inhibitors. | |
WO2004052853A3 (en) | Substituted 3-alkyl and 3-arylalkyl 1h-indol-1-yl acetic acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) | |
WO2004043456A8 (en) | Cholesterol absorption inhibitors for the treatment of demyelination | |
PT1206444E (en) | COMPOUNDS THAT INHIBIT TRIPTASE ACTIVITY | |
TW200503689A (en) | Pharmaceutical compositions of atorvastatin | |
HUP9801022A2 (en) | Use of aldose reductase inhibitor in preventing or reversing diabetic cardiomyopathy | |
TW200503690A (en) | Pharmaceutical compositions of atorvastatin | |
WO2001080813A3 (en) | Methods for preventing and treating alopecia induced by chemotherapy or radiotherapy | |
WO2001000197A3 (en) | Methods of treating fungal infections with inhibitors of nad synthetase enzyme | |
GB2426707A (en) | A stable parental formulation of levomepromazine and a method for stabilizing said formulation | |
NO20035038D0 (en) | Prevention of addiction to pain management | |
WO2001055176A3 (en) | Methods for inhibiting smooth muscle cell proliferation | |
WO2005041886A3 (en) | Methods for generating or increasing revenues related to pain inhibitor commerce | |
PL369772A1 (en) | Compounds that inhibit factor xa activity | |
WO2001043761A3 (en) | Methods for treating and preventing damage to mucosal tissue | |
WO2001055108A3 (en) | Use of spl a2 inhibitors for the treatment of inflammation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |